PLSE - רווח נקי למניה (EPS TTM) Pulse Corp

Pulse Biosciences, Inc. (PLSE) is establishing its pricing power in cardiology by offering flexible terms for the implementation of its developments. The EPS trend over the last 12 months, based on GURU.Markets data, reflects profit dynamics where the parameter value equals -1.21. The company is creating unrivaled tumor treatment protocols through cellular reprogramming, building a closed surgical loop based on the CellFX platform.

Net income per share over the last 12 months measures the actual return on each unit of capital by dividing the company's total net income by the total number of outstanding shares. By analyzing the rolling annual EPS trend, an investor assesses the monetization of Pulse Biosciences, Inc. (PLSE) innovations in implementing nanosecond pulses into tumor treatment protocols, determining the stage of the cell reprogramming ecosystem's transition to profitability.